Obesity and Prognostic Variables in Colombian Breast Cancer Patients: A Cross-Sectional Study

Abstract

Introduction Obesity is an established risk factor for cancer and cancer-related deaths, including that of the breast. While the prevalence of female obesity has accelerated over the past decade in many developing countries, such as Colombia, the prevalence of overweight and obesity specifically in breast cancer populations has not been fully described. Methods A cross-sectional study including 849 women diagnosed with breast cancer between 2009 and 2014. Based on body mass index, prevalence of overweight (BMI ≥ 25 < 30) and obesity (BMI ≥ 30) and associations of BMI with clinical and tumor histopathological features were analyzed. Results Colombian breast cancer patients had a prevalence of overweight of 34.28% and obesity of 28.15%. Mean BMI was comparable between premenopausal and postmenopausal women (27.2 versus 27.7, resp.). Among premenopausal women, higher BMI was significantly positively associated with hormone receptor negative tumors, as well as with greater lymphovascular invasion. Conclusions Colombian breast cancer patients exhibit a significant prevalence of overweight and obesity. Associations of high BMI and poor prognosis variables in the premenopausal population suggest risk of aggressive disease in this population. Future studies to further validate our observations are warranted in order to implement multidisciplinary clinical guidelines.

Variabilidad del peso en mujeres con cáncer de mama (IIIB), después de tratamiento

“…Es importante comparar los resultados reportados por Cuello-López y Cols, que presentaron un estudio que analizó el peso como variable de pronóstico en Colombianas, valiéndose de un diseño de corte transversal en 2017 (12), que mostró que pacientes posmenopáusicas de un centro oncológico en Medellín presentaron una asociación positiva entre IMC y subtipo luminal A. En el mismo trabajo se encontró una baja prevalencia (1.53%) de mujeres con cáncer de mama con bajo peso, mientras que hubo una alta frecuencia (65.4%) de sobrepeso/obesidad, similar a lo descrito en nuestra investigación.…”

Metformin as an adjuvant therapy to an aromatase inhibitor in overweight and obese postmenopausal women with breast cancer: A pilot study

“…The metformin arm had a nonsigni cantly greater incidence of side events than the other two arms (p > 0.05). The reported adverse effects are illustrated in Table (4).…”

“…Obesity is considered a risk factor for cancer and cancer-related mortality [4]. Obesity is usually associated with poor prognosis particularly in postmenopausal breast cancer females.…”

Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study

“…Obesity is considered a risk factor for cancer and cancerrelated mortality [5]. Obesity is usually associated with poor prognosis, particularly in postmenopausal women with breast cancer.…”